US 12,377,127 B2
Treatment for diseases caused by RNA virus SARS-CoV-2
Oral Alpan, Fairfax, VA (US); and Matthew Plassmeyer, Fairfax, VA (US)
Assigned to Amerimmune, LLC, Fairfax, VA (US)
Filed by Amerimmune, LLC, Fairfax, VA (US)
Filed on Feb. 15, 2023, as Appl. No. 18/169,473.
Application 18/169,473 is a continuation of application No. 17/919,020, previously published as PCT/US2021/027195, filed on Apr. 14, 2021.
Claims priority of provisional application 63/014,109, filed on Apr. 22, 2020.
Claims priority of provisional application 63/009,786, filed on Apr. 14, 2020.
Claims priority of provisional application 63/161,905, filed on Mar. 16, 2021.
Claims priority of provisional application 63/109,867, filed on Nov. 4, 2020.
Claims priority of provisional application 63/109,320, filed on Nov. 3, 2020.
Claims priority of provisional application 63/055,310, filed on Jul. 22, 2020.
Claims priority of provisional application 63/047,888, filed on Jul. 2, 2020.
Prior Publication US 2023/0190858 A1, Jun. 22, 2023
Int. Cl. A61K 31/4025 (2006.01); A61K 38/05 (2006.01); A61K 45/06 (2006.01); A61P 11/00 (2006.01); A61P 31/14 (2006.01); C12Q 1/37 (2006.01)
CPC A61K 38/05 (2013.01) [A61K 31/4025 (2013.01); A61K 45/06 (2013.01); A61P 11/00 (2018.01); A61P 31/14 (2018.01); C12Q 1/37 (2013.01); C12Y 304/22036 (2013.01)] 17 Claims
 
1. A method of treating a human subject that has an illness caused by a SARS-COV-2 virus infection of the subject, the method comprising:
administering to the human subject an amount of an inhibitor that inhibits an activity of at least two human caspase isoforms, wherein the amount is effective to reduce pyroptosis of T cells;
wherein at least one of said human caspase isoforms is human caspase 1, and
wherein the human subject has a condition in which caspase 1 activity or caspase 1 expression is increased in immune cells of the human subject.